DGAT inhibitors for obesity
Daisuke Matsuda1, Hiroshi Tomoda
1Kitasato University, School of Pharmacy, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.
Current Opinion in Investigational Drugs (London, England : 2000)
|October 2, 2007
Summary
Diacylglycerol acyltransferase 1 (DGAT1) inhibition is a potential strategy for obesity control. DGAT1 plays a role in very-low-density lipoprotein synthesis, which may promote obesity.
Area of Science:
- Biochemistry
- Metabolic Diseases
- Pharmacology
Background:
- Obesity is linked to triacylglycerol accumulation in adipocytes.
- Diacylglycerol acyltransferase (DGAT) is crucial for triacylglycerol synthesis.
- Two DGAT isozymes, DGAT1 and DGAT2, have been identified.
Purpose of the Study:
- To review DGAT inhibitors as potential anti-obesity therapeutics.
- To discuss the role of DGAT1 in very-low-density lipoprotein (VLDL) synthesis and obesity.
- To explore the therapeutic potential of DGAT1 inhibition for obesity management.
Main Methods:
- Literature review of DGAT inhibitors.
- Analysis of DGAT1 and DGAT2 roles in lipid metabolism.
- Discussion of natural and synthetic DGAT inhibitors.
Main Results:
- DGAT2 activity is associated with steatosis.
- DGAT1 is involved in VLDL synthesis; elevated VLDL may contribute to obesity.
- Various DGAT inhibitors have been identified.
Conclusions:
- DGAT1 inhibition presents a promising therapeutic target for obesity.
- Further research into DGAT inhibitors is warranted for anti-obesity drug development.
Related Concept Videos
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
211
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
211
01:23Dipeptidyl Peptidase 4 Inhibitors
540
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
540
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
496
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
496
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
554
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
554
01:24Glucagon-like Receptor Agonists
809
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
809
01:06Oral Hypoglycemic Agents: Glinides
554
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
554